Marshall Edwards Inc.

Overview

Treatments

Do you have histologically-confirmed ovarian, Fallopian, or primary peritoneal carcinoma of epithelial origin?

Do you have recurrent or persistent advanced ovarian cancer?

Do you have measurable disease (at least one lesion that can be accurately measured by CT or MRI)?

Have you had at least two courses of therapy with a platinum drug (cisplatin or carboplatin) and responded to the first of those courses of therapy?

Shown disease relapse within 6 months of completion of the second or greater course of platinum therapy?

Has it been less than 6 months since your last dose of platinum therapy?

Date ended:

Must be within 6 months

Are you over 18?

Will you be able to understand the risks and benefits of the study and give written informed consent to participation?

Contact Details

Marshall Edwards, Inc.
140 Wicks Road
North Ryde NSW 2113
Australia

T: +61 2 8877 6196
F: +61 2 9878 8474

.	home : about us. : about phenoxodiol : the technology : newsroom : : how to invest : contact details : credits : email Marshall Edwards Inc. 2001 ©